Long-term metabolic and biochemical outcomes of pasireotide LAR in resistant acromegaly

Abstract excerpt

<title>Abstract</title> <p>Background Pasireotide long‑acting release (PAS‑LAR) is a second‑generation somatostatin receptor ligand approved for patients with acromegaly resistant/intolerant to first‑generation analogues or combination medical therapy. Real‑world evidence on its metabolic impact and tumour response remains limited. Objective To evaluate the long‑term efficacy, metabolic safety, and tumour effec...

Topics

Open a Topic to create a Post that cites this publication.

• Antineoplastic Agents, Hormonal
• Arrestins
• beta-Arrestins
• Neurosurgical Procedures
• Peptides, Cyclic
• raf Kinases
• Receptors, Somatostatin
• Somatostatin

Identifiers and source

Literature Corpus work

8b7ea17c-b44a-5c4c-84d4-d5ad175817c6

DOI

10.21203/rs.3.rs-9757417/v1